Indian drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers ...

The Bengaluru-based pharma company is run by Ajay Bhardwaj, a former Biocon executive, who is the founder, CEO and Managing Director at Anthem Biosciences. The company was incorporated in 2006.

Anthem Biosciences files for a $397 million IPO amid India’s record-breaking year for public listings. The Bengaluru-based ...

Indian contract drugmaker Anthem Biosciences files for $397 million IPO amid booming Indian market for public offerings.

The IPO is entirely an OFS, the company will not receive any funds from the issue and the proceeds will go to the selling ...

The latest health updates include Anthem Biosciences' IPO, France's bird flu outbreaks impacting disease-free status, China's ...

Anthem Biosciences has filed for a Rs 3,395-crore IPO consisting entirely of an offer for sale by promoters and shareholders. The funds will not benefit the company directly but go to selling parties.

(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public ...

Anthem Biosciences, a CRDMO specializing in drug discovery, development and manufacturing, has filed draft papers with Sebi ...

Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters ...

The proposed initial public offer (IPO) is entirely an offer for sale (OFS) worth ₹3,395 crore by promoters, investors and ...